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There have been notable advances in the development of vaccines against active tuberculosis
(TB) disease for adults and adolescents. Using mathematical models, we seek to estimate the
potential impact of a post-exposure TB vaccine, having 50% efficacy in reducing active
disease, on global rifampicin-resistant (RR-) TB burden. In 30 countries that together
accounted for 90% of global RR-TB incidence in 2018, a future TB vaccine could avert 10%
(95% credible interval: 9.7–11%) of RR-TB cases and 7.3% (6.6–8.1%) of deaths over 2020–
2035, with India, China, Indonesia, Pakistan, and the Russian Federation having the greatest
contribution. This impact would increase to 14% (12–16%) and 31% (29–33%) respectively,
when combined with improvements in RR-TB diagnosis and treatment relative to a scenario
of no vaccine and no such improvements. A future TB vaccine could have important impli-
cations for the global control of RR-TB, especially if implemented alongside enhancements in
management of drug resistance.
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The emergence of drug resistance poses a pressing challengein the control of tuberculosis (TB) worldwide1. In 2018, anestimated 500,000 incident TB cases worldwide (out of a
total of 10 million incident cases) were resistant to rifampicin,
one of the key drugs in first-line anti-TB treatment2. Second-line
treatment for these cases is costly, protracted and toxic, with an
average treatment success of only 56%, compared to 85% for
drug-sensitive TB2. Recent years have seen important advances in
the development of shorter and safer regimens for treatment of
rifampicin-resistant (RR-) TB3–5, as well as the potential for
regimens to avoid using ineffective drugs by early detection of
broader resistance profiles6,7; nonetheless, global uptake of these
new regimens remains slow3.
Prevention of drug-resistant TB may be as important as
improving patient outcomes for achieving desired reductions in
the burden of disease8. Although recent years have seen notable
advances in the development of simplified preventive regimens
against drug-sensitive TB9,10, preventive therapy against drug-
resistant infection is complicated by the fact that there is currently
no assay for latent TB infection (LTBI) that can determine drug
susceptibility of the infecting strain. In recent contacts of
multidrug-resistant TB, preventive treatment can be tailored to
the drug sensitivity status of the index case, but this approach
does not address those with immunity to TB-specific antigens and
no known contact. However, recent developments have raised the
prospect of prevention through vaccination11. Informed in part
by seminal modelling analysis12, in 2018 the World Health
Organization (WHO) defined a preferred product profile for TB
vaccine13. Amongst priorities for vaccine development, this
document identified the ability to protect adults and adolescents
with LTBI from developing the active form of the disease, with at
least 50% efficacy, and offering at least ten years of protection13.
In subsequent results from a phase 2b trial, amongst adults
and adolescents with LTBI in Kenya and South Africa, the
M72/AS01E (hereafter M72) vaccine decreased TB incidence by
almost half14.
By offering protection regardless of drug sensitivity status,
future TB vaccines may offer an important opportunity to
reduce the transmission of drug-resistant TB, as well as the
overall burden of TB. Prevention of TB through vaccination
may have the corollary benefit of reducing population-level
selection of resistant strains, as the use of anti-TB drugs
declines. However, the potential impact of a future TB vaccine
on the global burden of drug-resistant TB remains unknown.
It is also uncertain how the impact of such a vaccine may
compare with the uptake of new second-line regimens, that are
shorter, safer and potentially more effective than earlier regi-
mens involving injectable drugs5.
In the present work, we seek to address these questions using
mathematical modelling of TB transmission dynamics, in 30
countries with a high burden of drug-resistant TB (Table 1). We
modelled the potential impact of a rollout of an M72-like, ‘post-
exposure’ vaccine (i.e. one intended for use amongst those already
infected with TB) amongst adults and adolescents, and assessed
health impacts between 2020 and 2035, with a focus on RR-TB.
As a secondary analysis, we examined the potential contribution
of a TB vaccine, to antimicrobial resistance more broadly than
TB. There is evidence indicating that TB cases are often treated
with empiric antibiotic therapy in primary care settings15,
including the use of quinolones16,17. Therefore, if a vaccine
reduces overall TB burden, it may also reduce the prevalence of
symptoms that would trigger antibiotic consumption, reducing
selection for resistance not only in TB but other pathogens or
commensal bacteria that might be exposed18. We estimated the
potential impact of a future TB vaccine, on reducing antibiotic
consumption in this way.
Results
Overview. Supplementary Figs. 1–6 and Supplementary Table 1
show the results of model calibration in the 30 countries
accounting for 90% of RR-TB incidence in 2018, based on four
different model structures that capture variations in the epide-
miology of TB and health systems across these countries
(Table 1). Additional results show model validation with data that
was not used for calibration, including prevalence surveys where
available (Supplementary Fig. 7) and model-based estimates for
the proportion of incident, drug-resistant TB that arises through
transmission, rather than through treatment (Supplementary
Fig. 8). Figure 1 shows illustrative results for RR-TB incidence
trajectories in India, the Russian Federation, China, and Nigeria,
as example countries representing each of the model structures
(Table 1); Supplementary Fig. 9 shows these same dynamics, but
illustrating the cases averted over time.
Vaccine impact on RR-TB incidence. Figure 2 summarises the
overall impact in terms of cumulative RR-TB cases averted between
2020 and 2035, illustrating dominant contributions from India and
China, as well as from high-burden countries including Indonesia,
Pakistan, the Russian Federation and Nigeria. Globally, relative to a
status quo comparator, an M72-like vaccine would avert 620,000
cases (95% credible intervals [CrI]: 516,000–867,000) of RR-TB
between 2020 and 2035 (Table 2). Molecular diagnostic tools are
offering new opportunities for early recognition of rifampicin
resistance19, while new, shorter, safer second-line regimens may
facilitate improved treatment outcomes5. If use of an M72-
like vaccine is combined with increased uptake of these tools (i.e.
improved management of RR-TB), the overall impact would
increase to 831,000 RR-TB cases (95% CrI: 643,000–1,170,000)
averted.
Figure 3 shows percent reductions of RR-TB cases by country.
Globally, the effect of vaccination would be to avert 10% (95%
CrI: 9.7–11%) of RR-TB cases between 2020 and 2035, relative to
a status quo comparator (Table 2). Combined with improved RR-
TB management, this impact would increase to 14% (95% CrI:
12–16%) of RR-TB cases. For countries having only small
improvement gaps in coverage of drug susceptibility testing and
success of second-line treatment, like Myanmar and Kazakhstan
(Supplementary Fig. 10), improved management of RR-TB would
have only limited incremental impact on RR-TB burden, in
addition to vaccination. Supplementary Fig. 11 illustrates that, at
the global level, ~2500 adolescents and adults with LTBI would
need to be vaccinated to avert 1 RR-TB case.
Vaccine impact on RR-TB mortality. Figures 4 and 5 show
corresponding results in terms of RR-TB mortality: globally,
vaccination would avert 119,000 (95% CrI: 96,000–174,000) RR-
TB deaths between 2020 and 2035, amounting to a reduction of
7.3% (95% CrI: 6.6–8.1%). Improvement in RR-TB management
showed a greater impact on preventing mortality than incidence
of RR-TB burden. When combined with vaccination, 499,000
(95% CrI: 391,000–729,000) RR-TB deaths would be averted
between 2020 and 2035, amounting to a reduction of 31% (95%
CrI: 29–33%) (Table 2). Supplementary Fig. 11 illustrates that, at
the global level, ~13,000 adolescents and adults with LTBI would
need to be vaccinated to avert 1 death from RR-TB. This estimate
may vary by local settings, depending on country-specific rates of
TB mortality.
In all of these estimates we assumed the vaccine would have the
same efficacy amongst individuals with and without human
immunodeficiency virus (HIV) infection. Supplementary Table 2
shows sensitivity analyses when assuming that vaccine efficacy is
reduced by half amongst those with HIV. Such a scenario shows
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20731-x
2 NATURE COMMUNICATIONS |          (2021) 12:424 | https://doi.org/10.1038/s41467-020-20731-x | www.nature.com/naturecommunications
Table 1 List of the 30 countries selected for the modelling analysis.
Countries having a strong private
healthcare sector (i)
Countries where HIV is a driver of TB
epidemiology (ii)
Countries with both a private sector









• Russia Federation (RUS)
• Ukraine (UKR)
• South Africa (ZAF)
• Mozambique (MOZ)







• Viet Nam (VNM)






• Papua New Guinea (PNG)
• Tajikistan (TJK)
• Belarus (BLR)
• Republic of Moldova
(MDA)
• Azerbaijan (AZE)
These are the countries with the largest absolute burden of RR-TB, and that accounted in 2018 for 90% of global RR-TB incidence (Supplementary Fig. 16). The table shows countries grouped into four
different categories, for the purpose of modelling. The ISO alpha-3 code for each country is also shown in brackets. We developed a specific model structure for each of the country categories, and
calibrated that model separately for each country within each category. Footnotes: (i) We drew these countries from the World Health Organization list of priority countries for public-private-mix
programmes46, namely those countries where the private sector plays a strong role in managing TB patients, and which account for the bulk of unreported cases globally. (ii) We identified these
countries as those in which HIV coinfection accounted for at least 10% of estimated TB incidence in 2018.
HIV human immunodeficiency virus, RR-TB rifampicin-resistant tuberculosis.
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Fig. 1 Illustration of the projected impact on RR-TB of an M72-like vaccine. n= 200 posterior samples. Median (solid and dashed lines) and 95%
Bayesian credible intervals (CrIs) of rifampicin-resistant tuberculosis (RR-TB) incidence rates over 2019–2035 are presented. For clarity, uncertainty
regions with CrIs are only shown for the vaccine (not comparator) scenarios. These projections correspond to a post-exposure vaccine that reduces the
risk of reactivation of latent TB infection by 50%, and that is implemented through routine vaccination and catch-up campaign amongst those over 15-years
old. The figure shows projections for the countries with the highest absolute burden of RR-TB from each of the country categories listed in Table 1. Blue
dashed curves illustrate a ‘status quo’ baseline, assuming no vaccine implementation and no change in the management of RR-TB. Blue solid curves show
the impact of vaccination. Red curves show corresponding dynamics, under an alternative ‘improved RR-TB management’ baseline where the detection of
RR-TB at the point of TB diagnosis is increased to 85%, and second-line treatment success is increased to 75%, in countries that have not yet achieved
these targets. The Russian Federation in particular shows a lower impact of improved RR-TB management than other countries, owing to its already-higher
coverage of drug susceptibility tests (Supplementary Fig. 10). Although the 95% CrIs for these projected dynamics with vaccination overlap in these
regions, the overall incidence reductions are significant, in the sense of having uncertainty intervals that are strictly positive (Table 2, Supplementary
Fig. 9).
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only a modest effect on the global impact of vaccination on RR-
TB: for example, with 10% (95% CrI: 9.7–11%) cases averted
under the status quo scenario, being reduced to 10% (95% CrI:
9.5–11%).
Vaccine impact on antibiotic consumption. Supplementary
Fig. 12 and Supplementary Table 3 additionally illustrate how
vaccination reduces the total amount of second-line TB treatment
needed, because of its impact on RR-TB. By contrast, efforts to
improve the management of RR-TB would increase the demand
for second-line drugs, as a result of increased identification of
resistant cases (Supplementary Table 4). Finally, Supplementary
Fig. 13 illustrates that future TB vaccines are likely to have only
modest impact on antibiotic consumption beyond TB drugs,
typically amounting to <1% of total estimated antibiotic con-
sumption in each country. This limited impact arises because
of the relative rarity of TB amongst those with respiratory
symptoms receiving antibiotics, when compared against other
aetiologies such as acute respiratory infections.
Discussion
Our results suggest that an M72-like vaccine, when deployed as a
post-exposure vaccine amongst adults and adolescents, could
have an important impact on drug-resistant TB. Such a vaccine,
acting alone, could avert 10% (95% CrI: 9.7–11%) of cumulative
RR-TB cases over the next 15 years. Indeed, this impact is
comparable to that of combining improvements in the manage-
ment (detection and treatment) of RR-TB, projected to be 14%
(95% CrI: 12–16%) of RR-TB cases over the same period
(Table 2). The combined effect of vaccination and improved
management is roughly additive (Figs. 3 and 5).
The impact of vaccination on relative reductions in RR-TB
burden is roughly consistent across countries, reducing RR-TB
cases between 5 and 16% (Fig. 2). Similar figures apply to relative
reductions in RR-TB deaths (Fig. 4). In terms of country con-
tributions to the projected global impact of vaccination, India and
China are consistently the leading countries (Figs. 2 and 4), owing
to their relatively large shares of global TB burden2. Countries in
the former Soviet Union have the world’s highest rates of drug
resistance amongst TB cases, however, their relative contributions
to the global vaccine-avertable burden of RR-TB are lower, as a
result of having smaller TB epidemics in absolute terms2.
We have presented results for the number of second-line TB
treatments that would be avertable by a TB vaccine between 2020
and 2035, but a cost impact is outside the scope of this study. This
is an important component of any costing analysis, because of the
disproportionate cost of managing drug-resistant TB, for any
national TB programme20,21. Notably, our results illustrate that—
while vaccination could reduce the need for second-line drugs by
reducing incidence of RR-TB—measures to improve the detection
of RR-TB would have the opposite effect, by increasing the
number of patients needing to be treated with second-line drugs
(Supplementary Fig. 12). Appropriate TB treatment is critical for
patient outcomes7,22. However, our results illustrate that a com-
bined strategy—of vaccination with improved RR-TB manage-
ment—could help to mitigate the budgetary burden on TB
programmes, by reducing overall RR-TB burden while minimis-
ing the numbers of second-line treatments required (Table 2,
Supplementary Fig. 12). Any resulting cost savings would release
programmatic funds, potentially for other TB control efforts such
as intensified case-finding that could—in turn—have a synergistic
effect on reducing the burden of drug-resistant TB.
As a grounding example for our analysis, we have drawn data
from the phase 2b trial of the M72/AS01E vaccine, which was
limited to individuals with evidence of latent TB infection.
Accordingly, we modelled a scenario where a vaccine is deployed
solely for post-exposure protection, i.e. to reduce the risk of TB
disease amongst those already infected. We expect that incor-
porating pre-exposure protection, and broadening eligibility to
include all individuals regardless of infection status, would sub-
stantially increase the projected impact of vaccination. Future
trial data will be valuable in informing these projections. Another
important area for future work is the feasibility of, and best
implementation strategies for, the type of mass vaccination pro-
gramme considered here. School-based vaccination may be
important in reaching 15-year-olds, and is already used for the
delivery of tetanus and HPV vaccines in low- and middle-income
countries23,24. To ensure equitable access, however, such strate-
gies will need to be supplemented by additional measures such as
mobile vaccine delivery, to reach those not in the school system.
Supplementary analysis illustrates the importance of mass vac-
cination campaigns amongst adults, showing that without these
additional efforts, overall impact on RR-TB incidence and mor-
tality would drop by 85% (Supplementary Table 2). In practice,
such catch-up efforts would need to be planned carefully: the
existing coverage of adult immunisation in countries such as
Fig. 2 Country-wise contribution to vaccine-avertable incidence of RR-TB. The area of each square is proportional to the median estimate from n= 200
posterior samples, for the absolute number of avertable rifampicin-resistant tuberculosis (RR-TB) cases by a post-exposure, M72-like vaccine, between
2020 and 2035. Panel a shows cases averted by a vaccine alone, while panel b shows cases averted by a combination of a vaccine and measures to
improve the management of RR-TB (both relative to a scenario of no vaccine, and no improvement in RR-TB, i.e. status quo). Countries are denoted by their
ISO alpha-3 codes and their corresponding full names are listed in Table 1. Colours for each country are only for the purpose of display, and do not
designate any quantitative scale.
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India presents substantial challenges25,26, which would likely
apply to a future TB vaccine as well. In both types of vaccination
effort, there are important considerations around whether the
vaccine should be offered only to those with evidence of LTBI, or
regardless. In the present work, we have assumed the former, a
choice necessitated by the available data: the recent phase 2b trial
of the M72/AS01E vaccine was restricted to those with LTBI14. As
more data emerges about the effectiveness of the vaccine in
uninfected individuals, an important area for further analysis
would be the relative value of limiting vaccination coverage to
those with LTBI (incurring the cost and effort of identifying these
individuals), vs universal eligibility within defined age groups
(incurring the cost of additional vaccinations). The per-dose cost
of any future TB vaccine will likely be a driving factor in these
considerations.
Another approach to prevention, currently part of WHO
guidelines for programmatic management of TB, is the use of
preventive therapy regimens amongst those known to have TB
infection27. Although recent years have seen the emergence of
shortened and simplified preventive therapy regimens9,10, these
are rifampicin-based regimens, and thus unlikely to be effective
against RR-TB infection. There is increasing recognition of the
potential value of fluoroquinolone-based preventive regimens
amongst contacts of those with known drug-resistant TB28,29
although there remains a pressing need for more clinical trials to
demonstrate efficacy8. On the other hand, by preventing TB at the
population level, not just amongst contacts of known cases, a
future vaccine might have further-reaching impact than pre-
ventive therapy: however, a strategy, such as the one we have
modelled here, may take several years to fully realise this impact
(Supplementary Fig. 9). Any future strategy for TB prevention is,
therefore, likely to require a combination of preventive therapy
and vaccination.
In addition to mass vaccination, supplementary immunisation
approaches may also have an important impact, for example,
vaccination of close contacts of diagnosed TB cases. Recent mod-
elling work (albeit in the context of preventive therapy) suggests
that preventing 60% of incident TB amongst household contacts of
TB cases in the WHO South-East Asian Region could reduce
annual incidence rates in the Region by ~8%, by 203030. That
analysis assumed preventive therapy to be ineffective amongst
those with drug-resistant infection; a vaccine in place of preventive
therapy, therefore, might be expected to have a similar impact on
RR-TB, if not higher. Our analysis also does not address the
potential use of therapeutic vaccination, that is administered fol-
lowing completion of treatment for active TB, in order to minimise
the risk of recurrence31. By potentially reducing the risk of
treatment-acquired drug resistance developing into active, infec-
tious TB, such approaches could also have important implications
for future RR-TB incidence.
Our focus on post-exposure vaccination amongst adults and
adolescents with LTBI is motivated by the recent phase 2b trial of
the M72 vaccine14, which suggested a 50% reduction in incidence
amongst those receiving the vaccine. However, these numbers
should be interpreted with caution, primarily because they come
from a trial that was only designed to assess safety and immu-
nogenicity, not efficacy; larger trials are needed to estimate pro-
tective efficacy with precision. Moreover, the protective effect was
seen mostly after a year, in males and those under 25 years of age.
The study was conducted in South Africa, Kenya and Zambia,
settings with a high overall burden of TB (for example with South
Africa having an annual TB incidence of 520 per 100,000 popu-
lation2), and it is unclear how these findings might generalise to
other settings. Therefore, phase 3 trial results in different settings
will be invaluable in gaining more reliable estimates of efficacy.
These limitations notwithstanding, our modelling results would
apply generally to any post-exposure vaccine having 50% efficacy
amongst adults and adolescents. For the purpose of our current
study, the important findings reported in ref. 14 show that such a
vaccine is indeed plausible.
As with any modelling analysis, our work has some limitations
to note. For simplicity, and to cover 30 countries in a systematic
way, we captured key features of TB transmission with four dif-
ferent model structures, using country-specific calibrations. Some
model parameters are subject to substantial uncertainty, such as
the quality of TB care in the private healthcare sector; we have
aimed to address this uncertainty by adopting wide uncertainty
intervals for these parameters (Supplementary Table 5), and by
propagating this uncertainty to model projections using Bayesian
calibration methods. For simplicity we adopted a simple model
mechanism for ageing, assuming a constant per-capita hazard of
transitioning between child and adult strata. This simplification
allows us to accommodate additional, country-specific complex-
ities such as public and private healthcare providers, and the role
of HIV in driving TB dynamics. Nonetheless, our results for TB
impact remain broadly consistent with those reported in earlier
studies which use more complex demographic structure12. In the
case of China, where most TB burden is concentrated in those
aged over 65 years, additional sensitivity analysis suggests that
model results do not change substantially, with the inclusion of a
third age group to represent the elderly (Supplementary Fig. 14).
Our model also entails simplifications around HIV and TB,
adopting a relatively simple HIV care cascade (Supplementary
Fig. 15c), as well as borrowing from previous work32 to incor-
porate simplified scenarios for the scale-up and maintenance of
antiretroviral treatment (ART) (Supplementary Methods 1).
Sensitivity analysis suggests that the influence of HIV on effec-
tiveness of a future TB vaccine would have important implica-
tions for vaccine impact in countries with high HIV burden but
would not substantially change our estimates for vaccine impact
at the global level (Supplementary Table 2).
Such limitations notwithstanding, the essential findings of our
analysis are likely to hold true: that an M72-like vaccine, even
with an efficacy of only 50%, at 72–76% coverage of LTBI ado-
lescents and adults, would have an important impact on the
global burden of RR-TB, as well as important synergistic effects
with ongoing efforts to improve the detection and treatment of
RR-TB. As with many challenges in TB control, optimal control
strategies in the future are likely to involve a combination of
different approaches: our work illustrates the critical role that
vaccination could play, as part of these strategies.
Methods
Model structure. We limited our analysis to the 30 countries shown in Table 1 and
Supplementary Fig. 16, which together accounted for 90% of global RR-TB inci-
dence in 20182. To account for the wide variation in TB epidemiology and health
systems between these different countries, we developed four different TB models,
relating to each of the categories shown in Table 1, and described in further detail
in Supplementary Methods 1. For countries where HIV is a driving factor in TB
burden (Supplementary Fig. 17), we modelled the historical dynamics of HIV using
data obtained from The Joint United Nations Programme on HIV/AIDS
(UNAIDS)33. We also modelled the impact of HIV on TB progression, as well as
the mitigating effect of ART and isoniazid preventive therapy for TB (assuming
such preventive therapy to be effective only against drug-sensitive infection). We
did not explicitly model the dynamics of HIV and ART, instead taking these as
model inputs. For countries where the private sector has a substantial presence, we
distinguished between those receiving care in the public and private sectors, and
assumed a lower standard of TB care in the latter than in the former34–37. Given
little systematic data for care provided by the private sector in different countries,
we adopted broad uncertainty intervals for the accuracy of TB diagnosis and for
treatment completion rates in this sector.
For each of four TB models we stratified the population into those above and
below 15 years of age, and modelled ageing as a constant rate-of-transition between
these strata, chosen to capture the country demographics as of 201838. Model
equations and parameters can be found in Supplementary Methods 1, Supplementary
Fig. 15, and Supplementary Tables 5, 6.
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Data and calibration. For each country we calibrated the model to a range of
epidemiological and programmatic indicators, including the WHO estimates for
TB incidence and mortality, stratified by age group; the proportion of incident TB
cases being RR-TB; and the proportion of TB incidence that occurred in those
coinfected with HIV (Supplementary Table 7). For countries having a strong
private sector healthcare presence, we assumed that all those surviving to the point
of care-seeking are managed by either the public or private sector: by combining
data for public sector notifications with model projections for incidence and
mortality, therefore, we aimed to estimate the proportion of patients being man-
aged by the public vs private sectors. For countries with a driving role of HIV in the
TB epidemic, we obtained ART coverage from UNAIDS, for simplicity assuming a
linear scale-up to current levels32. We calibrated the model using Adaptive Markov
Chain Monte Carlo39, which allows systematic propagation of uncertainty from
model inputs to model projections, while updating the proposal distribution at
each iteration. We reduced autocorrelation by taking every 150th sample and
discarded the first 20,000 samples, to yield 200 samples overall (Supplementary
Methods 2). We calculated 2.5th and 97.5th percentiles as the 95% credible
intervals, and the 50th percentile as point estimates, on these samples and on
model projections. As a form of model validation, we compared model projections
for TB prevalence to findings from prevalence surveys, where available. For any
countries where model-projected prevalence did not match those from the pre-
valence surveys (in particular, where the uncertainty intervals did not overlap), we
recalibrated the models using the prevalence survey data, to ensure consistency
with all available information.
Intervention simulations. Consistent with the WHO preferred product char-
acteristics13 and the outcome of the M72/AS01E trial14, we assumed that the effect
of the vaccine is to attenuate the rates of primary progression and reactivation of
latent TB amongst adults and adolescents, thereby reducing TB incidence rates
amongst those vaccinated by 50%. We did not consider the vaccine protection
against recurrence of TB. We assumed an average duration of protection of 10
years, and that after this period, vaccinated individuals revert to their unvaccinated
status of LTBI. In the main analysis, we assumed for simplicity that the effec-
tiveness of a future TB vaccine would be unaffected by the HIV status of recipients.
Currently, there is no evidence for the effect of HIV coinfection on the perfor-
mance of M72-like vaccines, as the recent phase 2b trial was limited to HIV-
negative individuals. However, the RTS,S malaria and pneumococcal conjugate






















































































M72-like vaccine Improved RR-TB management Incremental effect of M72-like vaccine 95% CrI
Relative to status quo
Fig. 3 Projected percent cases of RR-TB averted by an M72-like vaccine. Rectangular bars show median estimates and error bars show 95% Bayesian
credible intervals (CrIs), both estimated from n= 200 posterior samples for each country. Blue bars show the vaccine-avertable proportions of rifampicin-
resistant tuberculosis (RR-TB) cases relative to a ‘status quo’ scenario, while adjacent bars together show averted proportions in combination with
‘improved RR-TB management’, as outlined in the caption to Fig. 1. The latter bars are stratified to show: (i) the impact of improved management of RR-TB
alone, i.e. in the absence of vaccination (orange segment), and (ii) the incremental impact of vaccination, acting in combination with these improvements
(red segment). Error bars on the stacked orange and red bars show the 95% CrIs of the total impact of a vaccine combined with improved management of
RR-TB. Countries are ranked in a descending order according to the number of RR-TB incident cases in 2018.
Fig. 4 Country-wise contribution to vaccine-avertable deaths from RR-TB. As for Fig. 2, the area of each square here is proportional to the median
estimate from n= 200 posterior samples, for the absolute number of avertable rifampicin-resistant tuberculosis (RR-TB) deaths by a post-exposure, M72-
like vaccine, between 2020 and 2035. Panel a shows deaths averted by a vaccine alone, while panel b shows deaths averted by a combination of a vaccine
and measures to improve the management of RR-TB (both relative to a scenario of no vaccine, and no improvement in RR-TB, i.e. status quo). Countries are
denoted by their ISO alpha-3 codes and their corresponding full names are listed in Table 1. Colours for each country are only for the purpose of display,
and do not designate any quantitative scale.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20731-x ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:424 | https://doi.org/10.1038/s41467-020-20731-x | www.nature.com/naturecommunications 7
Therefore, as a sensitivity analysis, we modelled a scenario where a future TB
vaccine has half the efficacy amongst HIV positive individuals, compared to those
without HIV.
We assumed a routine TB immunisation programme which vaccinates
adolescents on their 15th birthday from 2025 to 2035, with country-specific
vaccination coverage derived from secondary school attendance42 (Supplementary
Fig. 18). In addition, to boost vaccine coverage among all adults over 15 years old,
we assumed 2-year catch-up campaigns, implemented every 5 years, with a peak
coverage of 72–76%, according to WHO region12. The peak coverage of these
campaigns was derived from earlier modelling work12, where the data were
extracted from previous rubella vaccination campaigns and adapted to a wider
target population of adults and adolescents. We projected the averted cumulative
incidence of RR-TB; the averted cumulative deaths; and the averted patient-months
of second-line TB treatment over 2020–2035. We assessed these outcomes with
respect to a ‘status quo’ comparator, assuming current TB services continue
indefinitely without change. We also considered an ‘improved RR-TB
management’ comparator, reflecting ongoing improvements in the management of
RR-TB, in particular assuming that 85% of TB diagnoses also receive drug
susceptibility testing for rifampicin resistance (for example, through the increased
use of molecular diagnostic tools19), and that second-line treatment success is
increased to 75% (resulting from adoption of new, second-line regimens5), from
2020 onwards. Supplementary Fig. 10 shows these indicators of RR-TB
management in relation to the levels currently reported by different countries.
Potential contribution to control of antibiotic consumption. Unnecessary anti-
biotic consumption is a key driver of antimicrobial resistance, more broadly than
TB. We additionally examined the potential for a future TB vaccine to reduce this
consumption through the bystander effect43: that is, as a result of reducing
symptomatic presentations for primary care, and thus reducing instances of
empiric antibiotic treatment. We used data from Demographic Health Surveys
(DHS)44, for the proportion of acute respiratory illness that is medically attended
and treated with antibiotics in different settings, together with estimates from the
Global Burden of Disease 2017 project45 for all-cause incidence of respiratory
disease in the same countries as those covered in the DHS data (Supplementary
Methods 3).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Country-specific data used in this study are publicly available and their sources are
summarised in Supplementary Table 7, including population statistics from the United
Nations World Prospect Project 2019 (http://population.un.org/wpp/); TB incidence,
mortality, and other programmatic indicators from the WHO Global Tuberculosis
Database (http://www.who.int/tb/data/en/); HIV prevalence and ART coverage from the
data tool of UNAIDS (http://aidsinfo.unaids.org/); and secondary school attendance
from the United Nations Children’s Fund (https://data.unicef.org/topic/education/
secondary-education/). For analysis of antibiotic consumption for cough-related diseases,
data were obtained from the DHS Program (http://dhsprogram.com/data/, through the
rdhs 0.6.3 package in R 4.0.2) and the Global Burden of Disease Study 2017 (http://ghdx.
healthdata.org/gbd-2017). Extracted data are also presented in Supplementary Table 7 or
available at https://github.com/hfu915/drtb_vacc. Source data are provided with
this paper.
Code availability
MATLAB codes for simulating TB dynamics and vaccine impacts are available at https://
github.com/hfu915/drtb_vacc.
Received: 20 July 2020; Accepted: 16 December 2020;
References
1. Dheda, K. et al. The Lancet Respiratory Medicine Commission: 2019 update:
epidemiology, pathogenesis, transmission, diagnosis, and management of
multidrug-resistant and incurable tuberculosis. Lancet Respir. Med. 7, 820–826
(2019).
2. World Health Organization. Global tuberculosis report 2019. https://apps.
who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1
(2019).
3. Gandhi, N. R., Brust, J. C. M. & Shah, N. S. A new era for treatment of drug-
resistant tuberculosis. Eur. Respir J. 52, https://doi.org/10.1183/
13993003.01350-2018 (2018).
4. Nunn, A. J. et al. A trial of a shorter regimen for rifampin-resistant
tuberculosis. N. Engl. J. Med. 380, 1201–1213 (2019).
5. World Health Organization. WHO consolidated guidelines on drug-resistant
tuberculosis treatment. https://apps.who.int/iris/bitstream/handle/10665/
311389/9789241550529-eng.pdf?ua=1 (2019).
6. Lange, C. et al. Perspectives for personalized therapy for patients with
multidrug-resistant tuberculosis. J. Intern. Med. 284, 163–188 (2018).
7. Zurcher, K. et al. Drug susceptibility testing and mortality in patients treated
for tuberculosis in high-burden countries: a multicentre cohort study. Lancet
Infect. Dis. 19, 298–307 (2019).
8. Fox, G. J. et al. Preventing the spread of multidrug-resistant tuberculosis and
protecting contacts of infectious cases. Clin. Microbiol. Infect. 23, 147–153 (2017).
9. Swindells, S. et al. One month of rifapentine plus isoniazid to prevent HIV-























































































M72-like vaccine Improved RR-TB management Incremental effect of M72-like vaccine 95% CrI
Relative to status quo
Fig. 5 Projected percent deaths from RR-TB averted, as a result of anti-TB vaccination. Rectangular bars show median estimates and error bars show
95% Bayesian credible intervals (CrIs), both estimated from n= 200 posterior samples for each country. As in Fig. 3, blue bars here show the vaccine-
avertable proportions of rifampicin-resistant tuberculosis (RR-TB) deaths relative to a ‘status quo’ scenario, while adjacent bars show averted proportions
in combination with ‘improved RR-TB management’, as outlined in the caption to Fig. 1. The latter bars are stratified to show: (i) the impact of improved
management of RR-TB alone, i.e. in the absence of vaccination (orange segment), and (ii) the incremental impact of vaccination, acting in combination with
these improvements (red segment). Error bars on the stacked orange and red bars show the 95% CrIs of the total impact of a vaccine combined with
improved management of RR-TB. Countries are ranked in a descending order according to the number of RR-TB incident cases in 2018.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20731-x
8 NATURE COMMUNICATIONS |          (2021) 12:424 | https://doi.org/10.1038/s41467-020-20731-x | www.nature.com/naturecommunications
10. Sterling, T. R. et al. Three months of rifapentine and isoniazid for latent
tuberculosis infection. N. Engl. J. Med. 365, 2155–2166 (2011).
11. Kaufmann, S. H., Weiner, J. & von Reyn, C. F. Novel approaches to
tuberculosis vaccine development. Int. J. Infect. Dis. 56, 263–267 (2017).
12. Knight, G. M. et al. Impact and cost-effectiveness of new tuberculosis vaccines
in low- and middle-income countries. Proc. Natl. Acad. Sci. USA 111,
15520–15525 (2014).
13. World Health Organization. WHO preferred product characteristics for new
tuberculosis vaccines. https://apps.who.int/iris/bitstream/handle/10665/
273089/WHO-IVB-18.06-eng.pdf?ua=1 (2018).
14. Tait, D. R. et al. Final analysis of a trial of M72/AS01E vaccine to prevent
tuberculosis. N. Engl. J. Med. 381, 2429–2439 (2019).
15. Pai, M., Daftary, A. & Satyanarayana, S. TB control: challenges and
opportunities for India. Trans. R. Soc. Tropical Med. Hyg. 110, 158–160
(2016).
16. McDowell, A. & Pai, M. Treatment as diagnosis and diagnosis as treatment:
empirical management of presumptive tuberculosis in India. Int. J. Tuberc.
Lung D. 20, 536–543 (2016).
17. Satyanarayana, S. et al. Use of standardised patients to assess antibiotic
dispensing for tuberculosis by pharmacies in urban India: a cross-sectional
study. Lancet Infect. Dis. 16, 1261–1268 (2016).
18. von Gottberg, A. et al. Emergence of levofloxacin-non-susceptible
Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis
in children in South Africa: a cohort observational surveillance study. Lancet
371, 1108–1113 (2008).
19. Weyer, K. et al. Rapid molecular TB diagnosis: evidence, policy making
and global implementation of Xpert MTB/RIF. Eur. Respir. J. 42, 252–271
(2013).
20. Gunther, G., Gomez, G. B., Lange, C., Rupert, S. & van Leth, F., Tbnet.
Availability, price and affordability of anti-tuberculosis drugs in Europe: a
TBNET survey. Eur. Respiratory J. 45, 1081–1088 (2015).
21. Pooran, A., Pieterson, E., Davids, M., Theron, G. & Dheda, K. What is the cost
of diagnosis and management of drug resistant tuberculosis in South Africa?
PLoS ONE 8, e54587 (2013).
22. Cox, H. & Mizrahi, V. The coming of age of drug-susceptibility testing for
tuberculosis. N. Engl. J. Med. 379, 1474–1475 (2018).
23. Bundy, D. A. P. et al. Investment in child and adolescent health and
development: key messages from Disease Control Priorities, 3rd edition.
Lancet 391, 687–699 (2018).
24. Wigle, J., Coast, E. & Watson-Jones, D. Human papillomavirus (HPV) vaccine
implementation in low and middle-income countries (LMICs): health system
experiences and prospects. Vaccine 31, 3811–3817 (2013).
25. Dash, R. et al. Towards adult vaccination in India: a narrative literature review.
Hum. Vaccin. Immunother. 16, 991–1001 (2020).
26. Tan, L. J. Adult vaccination: now is the time to realize an unfulfilled potential.
Hum. Vaccin. Immunother. 11, 2158–2166 (2015).
27. World Health Organization. WHO consolidated guidelines on tuberculosis:
module 1: prevention: tuberculosis preventive treatment. https://www.who.int/
publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-1-
prevention-tuberculosis-preventive-treatment (2020).
28. Fox, G. J., Oxlade, O. & Menzies, D. Fluoroquinolone therapy for the
prevention of multidrug-resistant tuberculosis in contacts. A cost-effectiveness
analysis. Am. J. Respir. Crit. Care Med. 192, 229–237 (2015).
29. Malik, A. A. et al. Tuberculosis preventive therapy for individuals exposed to
drug-resistant tuberculosis: feasibility and safety of a community-based
delivery of fluoroquinolone-containing preventive regimen. Clin. Infect. Dis.
70, 1958–1965 (2020).
30. Mandal, S., Bhatia, V., Sharma, M., Mandal, P. P. & Arinaminpathy, N. The
potential impact of preventive therapy against tuberculosis in the WHO
South-East Asian Region: a modelling approach. BMC Med. 18, 163 (2020).
31. Vekemans, J. et al. Preferred product characteristics for therapeutic vaccines to
improve tuberculosis treatment outcomes: Key considerations from World
Health Organization consultations. Vaccine 38, 135–142 (2020).
32. Vesga, J. F. et al. Assessing tuberculosis control priorities in high-burden
settings: a modelling approach. Lancet Glob. Health 7, e585–e595 (2019).
33. UNAIDS. AIDSinfo. http://aidsinfo.unaids.org/ (2020).
34. Das, J. et al. Use of standardised patients to assess quality of tuberculosis care:
a pilot, cross-sectional study. Lancet Infect. Dis. 15, 1305–1313 (2015).
35. Sreeramareddy, C. T., Qin, Z. Z., Satyanarayana, S., Subbaraman, R. & Pai, M.
Delays in diagnosis and treatment of pulmonary tuberculosis in India: a
systematic review. Int. J. Tuberc. Lung Dis. 18, 255–266 (2014).
36. Wells, W. A., Uplekar, M. & Pai, M. Achieving systemic and scalable private
sector engagement in tuberculosis care and prevention in Asia. PLoS Med. 12,
e1001842 (2015).
37. Uplekar, M. Public-private mix for tuberculosis care and prevention. What
progress? What prospects? Int. J. Tuberc. Lung Dis. 20, 1424–1429 (2016).
38. United Nations Deparatment of Economic and Social Affairs. World
Population Prospects. https://population.un.org/wpp/ (2019).
39. Haario, H., Saksman, E. & Tamminen, J. An adaptive Metropolis algorithm.
Bernoulli 7, 223–242 (2001).
40. Otieno, L. et al. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine
in infants and children identified as HIV-infected during a randomized trial in
sub-Saharan Africa. Vaccine 38, 897–906 (2020).
41. Klugman, K. P. et al. A trial of a 9-valent pneumococcal conjugate vaccine in
children with and those without HIV infection. N. Engl. J. Med. 349,
1341–1348 (2003).
42. United Nations Children’s Fund. UNICEF Data: Secondary education. https://
data.unicef.org/topic/education/secondary-education/ (2019).
43. Lipsitch, M. & Siber, G. R. How can vaccines contribute to solving the
antimicrobial resistance problem? Mbio 7, https://doi.org/10.1128/
mBio.00428-16 (2016).
44. ICF. The DHS Program Data. https://dhsprogram.com/data/ (2019).
45. Global Burden of Disease Collaborative Network. Global Burden of Disease
study 2017 (GBD 2017) results. http://ghdx.healthdata.org/gbd-results-tool
(2018).




This work is funded by the Bill & Melinda Gates Foundation (OPP1190803). H.F. and
N.A. also acknowledge the Centre funding (MR/R015600/1) jointly from the UK Medical
Research Council (MRC) and the UK Foreign, Commonwealth & Development Office
(FCDO), under the MRC/FCDO Concordat agreement and also within the scope of the
EDCTP2 programme supported by the European Union.
Author contributions
R.L. and N.A. conceived the study. H.F. and N.A. developed the models, curated research
data, and performed the analysis. J.L., I.F. and R.L. provided validation of study findings
and input on model design. H.F. and N.A. prepared the first draft of the manuscript, and
all authors contributed to the revised manuscript.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-20731-x.
Correspondence and requests for materials should be addressed to H.F.
Peer review information Nature Communications thanks Roman Ragonnet, Bradly
Wagner, and the other, anonymous, reviewer(s) for their contribution to the peer review
of this work.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2021
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20731-x ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:424 | https://doi.org/10.1038/s41467-020-20731-x | www.nature.com/naturecommunications 9
